“Head and Neck Squamous Cell Carcinoma Market Insight, Epidemiology and Market Forecast – 2036,” provides a comprehensive assessment of the Head & Neck Squamous Cell Carcinoma market across the United States, EU4, the United Kingdom, and Japan. The report provides an in-depth analysis of historical and forecasted epidemiology, patient burden, treatment practices, market dynamics, emerging therapies, competitive intelligence, drug uptake, reimbursement, pricing, & unmet medical needs through 2036.

(Albany, New York) – 21st Sep 2026 – DelveInsight’s latest report, “Head and Neck Squamous Cell Carcinoma Market Insight, Epidemiology and Market Forecast – 2036,” provides a comprehensive assessment of the Head and Neck Squamous Cell Carcinoma (HNSCC) market across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The report provides an in-depth analysis of historical and forecasted epidemiology, patient burden, treatment practices, market dynamics, emerging therapies, competitive intelligence, drug uptake, reimbursement, pricing, and unmet medical needs through 2036.

According to DelveInsight, the HNSCC market size was valued at approximately USD 850 million in 2025 and is projected to reach nearly USD 2,560 million by 2036, expanding at a 10.5% CAGR during 2026–2036. The United States is expected to remain a major contributor to the HNSCC therapeutics market, with the US market projected to reach approximately USD 2,082 million by 2036.

Key Takeaways from the Head and Neck Squamous Cell Carcinoma Market

• The HNSCC market was valued at approximately USD 850 million in 2025.
• The market is projected to reach nearly USD 2,560 million by 2036.
• The market is expected to expand at a 10.5% CAGR during 2026–2036.
• The 7MM recorded approximately 153,500 incident HNSCC cases in 2025.
• More than 90% of oropharyngeal cancer cases in the US are attributed to HPV, with HPV16 accounting for approximately 90% of these cases.
• KEYTRUDA (pembrolizumab) and OPDIVO (nivolumab) are the primary PD-1 inhibitors approved for recurrent or metastatic HNSCC.
• KEYTRUDA is an important first-line treatment option for recurrent/metastatic HNSCC, particularly in patients with high PD-L1 expression.
• Petosemtamab, Versamune HPV (PDS0101), BNT113, amivantamab (RYBREVANT), and eftilagimod alfa are among the key emerging therapies.
• Major companies include Merck, Bristol Myers Squibb, Coherus BioSciences, Akeso Biopharma, Immutep, Merus N.V., NANOBIOTIX, Johnson & Johnson, PDS Biotechnology, and BioNTech.

Keen to know more about the Head and Neck Squamous Cell Carcinoma market? Request a sample copy of the report for detailed market insights, epidemiology, treatment patterns, competitive intelligence, and forecast analysis. https://www.delveinsight.com/sample-request/head-and-neck-squamous-cell-carcinoma-market

Key Factors Driving the Head and Neck Squamous Cell Carcinoma Market

Rising Incidence of Head and Neck Squamous Cell Carcinoma

The increasing burden of HNSCC is associated with established risk factors such as tobacco use and alcohol consumption, along with the growing contribution of human papillomavirus (HPV) infection. In particular, HPV-positive oropharyngeal cancers are reshaping the epidemiology of HNSCC and expanding the focus on HPV-specific treatment strategies.

The increasing recognition and diagnosis of HPV-associated disease are also supporting greater segmentation of patients according to HPV status, tumor site, and disease stage.

Reshaping of the Immunotherapy Landscape

Immunotherapy has become an important component of the HNSCC treatment paradigm. PD-1 inhibitors such as pembrolizumab and nivolumab have established roles in recurrent and metastatic disease, while research is increasingly moving toward earlier treatment settings and combination strategies.

The development of therapeutic vaccines targeting HPV16 oncoproteins E6 and E7 is another important area of innovation. Candidates such as ISA101, Versamune HPV, BNT113, abipapogene suvaplasmid, and INO-3112 are being evaluated to generate antigen-specific immune responses against HPV16-associated tumors.

Increasing Focus on HPV-positive HNSCC

HPV-positive HNSCC represents a biologically distinct subgroup, particularly within oropharyngeal cancers. The report highlights the potential of HPV-targeted therapies, therapeutic vaccines, and T-cell receptor-based approaches to address disease biology that is not fully addressed by current checkpoint inhibitors.

Although checkpoint inhibitors have improved outcomes, immune evasion and tumor microenvironment suppression can contribute to resistance, creating opportunities for combination and antigen-specific treatment strategies.

Development of Novel Targeted and Bispecific Therapies

The emerging HNSCC pipeline includes therapies designed to target alternative biological pathways and overcome resistance to existing treatment. Petosemtamab, for example, is designed to target EGFR and LGR5, while amivantamab targets EGFR and MET through a bispecific antibody approach.

These approaches could broaden treatment options for patients whose disease progresses following conventional chemotherapy or immune checkpoint inhibition.

Expansion of Therapeutic Vaccination Strategies

Therapeutic cancer vaccines are gaining momentum in HNSCC, particularly for HPV16-positive disease. The objective of these approaches is to generate robust, antigen-specific T-cell responses against HPV-associated tumor cells. The report identifies ISA Pharmaceuticals, PDS Biotechnology, BioNTech, Nykode Therapeutics, and Inovio Pharmaceuticals among companies developing HPV-targeted vaccine approaches.

Competitive Landscape

The HNSCC market comprises established immunotherapy products, targeted therapies, chemotherapy-based regimens, and a growing pipeline of therapeutic vaccines, bispecific antibodies, and immune-modulating therapies.

Key companies include:

• Merck
• Bristol Myers Squibb
• Coherus BioSciences
• Akeso Biopharma
• Immutep
• Merus N.V.
• NANOBIOTIX
• Johnson & Johnson
• PDS Biotechnology
• BioNTech
• and others.

The current marketed landscape is led by KEYTRUDA (pembrolizumab) and OPDIVO (nivolumab), while the emerging pipeline includes Petosemtamab, BNT113, Versamune HPV, amivantamab, eftilagimod alfa, SCG142, and other candidates.

Recent Developments in the Head and Neck Squamous Cell Carcinoma Market

• February 2026: The US FDA granted Breakthrough Therapy Designation to amivantamab and hyaluronidase-lpuj (RYBREVANT FASPRO) as monotherapy for adults with recurrent or metastatic HPV-unrelated HNSCC following progression on or after platinum-based chemotherapy and a PD-L1 or PD-1 inhibitor.
• August 2025: Merus announced that enrollment in the Phase III LiGeR-HN2 trial in HNSCC was expected to be completed by the end of 2025.
• May 2025: Merus announced plans to share a topline interim readout in 2026 for its Phase III petosemtamab trial in HNSCC.
• August 2025: NHS England announced that patients with advanced head and neck cancers would be fast-tracked into a trial of a new cancer vaccine as part of its cancer-trial matchmaking service.
• May 2025: Merus announced interim clinical data from its Phase II trial evaluating petosemtamab in combination with pembrolizumab in first-line PD-L1-positive recurrent/metastatic HNSCC; the data were subsequently presented at ASCO 2025.
• August 2025: Immutep announced positive and constructive feedback from the US FDA regarding future development of eftilagimod alfa in combination with KEYTRUDA for first-line recurrent/metastatic HNSCC patients with PD-L1 CPS <1.

What is Head and Neck Squamous Cell Carcinoma?

Head and Neck Squamous Cell Carcinoma is a group of malignancies originating from squamous cells lining structures of the head and neck, including the oral cavity, hypopharynx, nasopharynx, oropharynx, lip, nasal cavity, paranasal sinuses, and salivary glands.

HNSCC represents a significant global cancer burden, with incidence and mortality varying across geographic regions and demographic groups. The disease is more prevalent in certain populations, including men and older adults, while HPV-associated disease has become increasingly important, particularly in oropharyngeal cancers.

Diagnosis is generally confirmed through biopsy of the primary tumor or neck mass. Histopathological examination establishes squamous differentiation, while immunohistochemistry can support diagnosis in poorly differentiated tumors. HPV testing is mandatory for oropharyngeal and unknown-primary tumors, with p16 immunohistochemistry serving as the standard surrogate marker for HPV status.

Current Treatment Landscape

Treatment of HNSCC requires a multidisciplinary approach based on tumor location, disease stage, HPV status, patient characteristics, and treatment history.

For locally advanced disease, surgery and/or radiotherapy remain major treatment modalities. Platinum-based chemotherapy, particularly cisplatin, may be administered concurrently with radiotherapy or as part of adjuvant treatment. Definitive chemoradiation is also used in selected unresectable cases and organ-preservation strategies.

In recurrent or metastatic disease, immune checkpoint inhibitors have substantially changed the treatment landscape.

KEYTRUDA (Pembrolizumab)

KEYTRUDA is an anti-PD-1 monoclonal antibody that blocks interaction between PD-1 and its ligands PD-L1 and PD-L2, helping restore antitumor immune activity. The US FDA approved KEYTRUDA in June 2019 for first-line treatment of metastatic or unresectable recurrent HNSCC, including HPV-positive disease.

OPDIVO (Nivolumab)

OPDIVO is a PD-1 immune checkpoint inhibitor designed to restore antitumor immune responses. It has become an important treatment option across multiple cancers and is used in the HNSCC treatment landscape following platinum-based therapy.

Cetuximab and Chemotherapy

Cetuximab (ERBITUX) remains relevant in selected locally advanced and metastatic settings, while platinum-based chemotherapy combined with 5-fluorouracil continues to have a role, particularly in combination-based treatment approaches.

Head and Neck Squamous Cell Carcinoma Epidemiology

DelveInsight estimates that the total incident cases of HNSCC across the 7MM were approximately 153,500 in 2025. The epidemiology analysis examines patient burden across the United States, EU4, the UK, and Japan and evaluates disease according to anatomical site, HPV status, stage, and treated population.

Key epidemiological findings include:

• The 7MM recorded approximately 153,500 HNSCC incident cases in 2025.
• Among the EU4 and UK, oral cavity HNSCC represented the largest site-specific case segment in 2025.
• Germany accounted for approximately 2,700 oropharyngeal squamous cell carcinoma incident cases in 2025.
• Japan accounted for approximately 3,900 HPV16-positive OPSCC incident cases in 2025.

Epidemiology Segmentation

The DelveInsight report segments HNSCC epidemiology into:

• Total incident cases of Head and Neck Cancer
• Total incident cases of HNSCC
• Site-specific incident cases of HNSCC
• HPV-positive status-specific incident cases of HNSCC
• Stage-specific incident cases of HNSCC
• Total treated cases of HNSCC

Unmet Needs in Head and Neck Squamous Cell Carcinoma

Despite progress in immunotherapy and targeted treatment, significant unmet needs remain:

1. Limited specific treatment options for certain patient populations
2. Lack of reliable prognostic biomarkers
3. Need for personalized and age-specific treatment
4. Poor survival in advanced disease despite standard treatment
5. Challenges in early detection
6. Need for robust HPV-related biomarkers
7. Treatment resistance following checkpoint inhibition

These gaps are driving research into therapeutic vaccines, bispecific antibodies, novel immune-modulating agents, and precision-based treatment strategies.

Scope of the Head and Neck Squamous Cell Carcinoma Market Report

• Study Period: 2022–2036
• Historical Period: 2022–2025
• Forecast Period: 2026–2036
• Base Year: 2026
• Geographies: US, Germany, France, Italy, Spain, UK, and Japan
• HNSCC Market Size, 2025: ~USD 850 million
• Projected HNSCC Market Size, 2036: ~USD 2,560 million
• Market CAGR: 10.5% during 2026–2036
• US HNSCC Therapeutics Market Size, 2036: ~USD 2,082 million
• 7MM HNSCC Incident Cases, 2025: ~153,500
• Epidemiology Segmentation: Total incident HNSCC cases, site-specific cases, HPV-positive status-specific cases, stage-specific cases, and total treated cases
• Market Segmentation: Region/geographies and drugs/therapies
• Key Companies: Merck, Bristol Myers Squibb, Coherus BioSciences, Akeso Biopharma, Immutep, Merus N.V., NANOBIOTIX, Johnson & Johnson, PDS Biotechnology, BioNTech, and others
• Key Therapies: Nivolumab (OPDIVO), pembrolizumab (KEYTRUDA), Petosemtamab, Versamune HPV (PDS0101), BNT113, Amivantamab (RYBREVANT), Eftilagimod alfa, SCG142, and others
• Analysis: KOL views, SWOT analysis, reimbursement, conjoint analysis, unmet needs, market drivers and barriers, and epidemiological patient burden
• Key Strengths: Epidemiology-based bottom-up forecasting, AI-enabled market research, 11-year forecast, regional market outlook, patient burden assessment, treatment addressable market, competitive landscape, company insights, pricing and analogue assessment, therapy uptake, and peak patient share analysis.

To Know More About the Head and Neck Squamous Cell Carcinoma Market Report

Head and Neck Squamous Cell Carcinoma Market Insight, Epidemiology and Market Forecast – 2036

Table of Contents

1. Report Introduction
2. Executive Summary
3. Key Events
4. Epidemiology and Market Methodology
5. Head and Neck Squamous Cell Carcinoma Disease Overview
6. Causes, Risk Factors, Signs and Symptoms
7. Diagnosis and Diagnostic Algorithm
8. Treatment Landscape
9. Current Treatment Guidelines
10. Marketed Therapies
11. Emerging Therapies and Pipeline Analysis
12. Epidemiology and Patient Burden
13. Patient Journey
14. Market Size and Forecast
15. Drug Uptake and Patient Share
16. Competitive Landscape
17. Market Drivers and Barriers
18. Unmet Medical Needs
19. Market Access and Reimbursement
20. Pricing and Analogue Assessment
21. KOL and SME Insights
22. SWOT and Conjoint Analysis
23. Regional Market Analysis
24. Company and Therapy Profiles
25. Market Outlook
26. Conclusions and Strategic Insights

About DelveInsight

DelveInsight is a leading market research and consulting firm specializing in the life sciences and healthcare industries. Founded in 2014, the company provides comprehensive market intelligence, epidemiology, and insights across pharmaceuticals, biotechnology, medical devices, and emerging therapies. DelveInsight helps healthcare organizations make informed strategic decisions through data-driven research and industry expertise.

 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services